The Use of Post-transplantation Cyclophosphamide in Peripheral Blood HLA-matched Stem Cell Transplantation as Graft-versus-host Disease Prophylaxis in Patients With Malignant or Non-malignant Hematologic Disorders: A Single-center Experience of 52 Patients

被引:2
作者
Mahmoud, Hossam Kamel [1 ]
Fathy, Gamal Mohamed [2 ]
Elhaddad, Alaa [1 ]
Fahmy, Omar A. [3 ]
Abdel-Mooti, Mohamed [1 ]
Abdelfattah, Raafat [1 ]
Bokhary, Mahmoud [2 ]
机构
[1] Natl Canc Inst, Hematol & Bone Marrow Transplantat Unit, Cairo, Egypt
[2] Nasser Inst Hosp Res & Treatment, Hematol & Bone Marrow Transplantat Unit, Cairo, Egypt
[3] Cairo Univ, Fac Med, Hematol & Bone Marrow Transplantat Unit, Cairo, Egypt
关键词
aGVHD; cGVHD; HLA-matched; PTCY; Relapse; BONE-MARROW-TRANSPLANTATION; SEVERE APLASTIC-ANEMIA; ENGRAFTMENT KINETICS; MORTALITY; RECOVERY; OUTCOMES; AGENT;
D O I
10.1016/j.clml.2020.04.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study was to assess the efficacy of post-transplant cyclophosphamide as graft-versus-host disease (GVHD) prophylaxis in patients with malignant or non-malignant hematologic disorders who underwent allogenic hemopoietic stem cell transplantation. Fifty-two patients were enrolled in this study at Nasser Institute Hospital in Egypt. The 1-year incidence of acute GVHD and chronic GVHD was significantly lower than that of patients who received cyclosporine and methotrexate. Introduction: Studies addressing the utilization of post-transplant cyclophosphamide (CY) as graft-versus-host disease (GVHD) prophylaxis in allogeneic hemopoietic stem cell transplantation from matched sibling donors are limited and with controversial results. Chronic GVHD incidence necessitating systemic treatment is around 35% in peripheral blood stem cell transplantation (PBSCT) from human leukocyte antigen-matched sibling donors. Patients and Methods: In this study, high-dose CY was added to PBSCT aiming to reduce the incidence of GVHD to reach a lower figure compared with standard GVHD prophylaxis. Fifty-two patients with either benign or malignant hematologic disorders who underwent stem cell transplantation at Nasser Institute Hospital in Egypt from November 2017 to October 2018 were enrolled in this study. Fifty patients had fully human leukocyte antigen-matched siblings, whereas the remaining 2 patients had 1 locus class I mismatched donors. Pre-transplant conditioning regimen was fludarabine and busulfan (FLU/BU) in malignant cases (73.1%) and FLU/CY in benign hematologic disorders (26.9%) and 1 patient with hypocellular myelodysplastic syndrome. For GVHD prophylaxis, CY was given at a dose of 50 mg/kg/day on days 3 and 4 post-transplantation, and cyclosporine (CSA) starting day 5 in 96.1% of patients. For the 1-locus mismatched patients, both CSA and mycophenolate mofetil were administered starting day 5. Results: The 1-year incidence of acute GVHD (aGVHD) was 15.3% and for chronic GVHD (cGVHD) was 13.4%. Historical data of GVHD prophylaxis at our center using CSA and methotrexate showed an incidence of 37% for aGVHD and 33.9% for cGVHD. Conclusions: Post-transplant CY GVHD prophylaxis led to significantly less aGVHD (P = .03) and cGVHD (P = .04). (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:677 / 684
页数:8
相关论文
共 31 条
[11]   Post-Transplant Cyclophosphamide as Sole Graft-versus-Host Disease Prophylaxis Is Feasible in Patients Undergoing Peripheral Blood Stem Cell Transplantation for Severe Aplastic Anemia Using Matched Sibling Donors [J].
George, Biju ;
Nisham, P. N. ;
Devasia, Anup J. ;
Kulkarni, Uday ;
Korula, Anu ;
Lakshmi, Kavitha M. ;
Abraham, Aby ;
Srivastava, Alok ;
Mathews, Vikram .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) :494-500
[12]   Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation. [J].
Gooley, Ted A. ;
Chien, Jason W. ;
Pergam, Steven A. ;
Hingorani, Sangeeta ;
Sorror, Mohamed L. ;
Boeckh, Michael ;
Martin, Paul J. ;
Sandmaier, Brenda M. ;
Marr, Kieren A. ;
Appelbaum, Frederick R. ;
Storb, Rainer ;
McDonald, George B. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (22) :2091-2101
[13]  
Ho AD, 2019, METHODS MOL BIOL, V2017, P1, DOI 10.1007/978-1-4939-9574-5_1
[14]   Bortezomib is safe in and stabilizes pulmonary function in patients with allo-HSCT-associated pulmonary CGVHD [J].
Jain, Manu ;
Budinger, G. R. S. ;
Jovanovic, Borko ;
Dematte, Jane ;
Duffey, Sara ;
Mehta, Jayesh .
BONE MARROW TRANSPLANTATION, 2018, 53 (09) :1124-1130
[15]   Impact of CD34 subsets on engraftment kinetics in allogeneic peripheral blood stem cell transplantation [J].
Kamel, AM ;
El-Sharkawy, N ;
Mahmoud, HK ;
Khalaf, MR ;
El Haddad, A ;
Fahmy, O ;
Abd el Fattah, R ;
Sayed, D .
BONE MARROW TRANSPLANTATION, 2005, 35 (02) :129-136
[16]   Multi-Institutional Study of Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine Conditioning [J].
Kanakry, Christopher G. ;
O'Donnell, Paul V. ;
Furlong, Terry ;
de Lima, Marcos J. ;
Wei, Wei ;
Medeot, Marta ;
Mielcarek, Marco ;
Champlin, Richard E. ;
Jones, Richard J. ;
Thall, Peter F. ;
Andersson, Borje S. ;
Luznik, Leo .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (31) :3497-+
[17]   Post-Transplantation Cyclophosphamide for Tolerance Induction in HLA-Haploidentical Bone Marrow Transplantation [J].
Luznik, Leo ;
O'Donnell, Paul V. ;
Fuchs, Ephraim J. .
SEMINARS IN ONCOLOGY, 2012, 39 (06) :683-693
[18]   High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease [J].
Luznik, Leo ;
Bolanos-Meade, Javier ;
Zahurak, Marianna ;
Chen, Allen R. ;
Smith, B. Douglas ;
Brodsky, Robert ;
Huff, Carol Ann ;
Borrello, Ivan ;
Matsui, William ;
Powell, Jonathan D. ;
Kasamon, Yvette ;
Goodman, Steven N. ;
Hess, Allan ;
Levitsky, Hyam I. ;
Ambinder, Richard F. ;
Jones, Richard J. ;
Fuchs, Ephraim J. .
BLOOD, 2010, 115 (16) :3224-3230
[19]   Janus Kinase Inhibition for Graft-Versus-Host Disease: Current Status and Future Prospects [J].
Mannina, Daniele ;
Kroeger, Nicolaus .
DRUGS, 2019, 79 (14) :1499-1509
[20]   Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide [J].
McCurdy, Shannon R. ;
Kanakry, Christopher G. ;
Tsai, Hua-Ling ;
Gojo, Ivana ;
Smith, B. Douglas ;
Gladstone, Douglas E. ;
Bolanos-Meade, Javier ;
Borrello, Ivan ;
Matsui, William H. ;
Swinnen, Lode J. ;
Huff, Carol Ann ;
Brodsky, Robert A. ;
Ambinder, Richard F. ;
Fuchs, Ephraim J. ;
Rosner, Gary L. ;
Jones, Richard J. ;
Luznik, Leo .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (06) :1128-1135